Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.

Front Immunol · 2021 · PMC8631508 · PMID 34858389

Europe PMC DOI

hedged sentence

0.0860

closest p · 1.7× alpha

0.0860

boldest claim

The sentences

a positive trendp = 0.086so close (0.05 < p ≤ 0.1)

There was also a positive trend for PFS, with an mPFS of 9.3 months (95%CI, 3.3–25.4) in the former group and 2.0 months (95%CI, 1.7–13.2) in the latter group ( Figure 5B ) ( p = 0.086).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.